Gerhard Winter

List of Publications by Year
in descending order

179 papers	7,779 citations	50276 46 h-index	62596 80 g-index
181 all docs	181 docs citations	181 times ranked	7801 citing authors

#	Article	IF	Citations
1	Comparison of Submicron Particle Counting Methods with a Heat Stressed Monoclonal Antibody: Effect of Electrolytes and Implications on Sample Preparation. Journal of Pharmaceutical Sciences, 2022, 111, 1992-1999.	3.3	1
2	Investigation of the pH-dependent aggregation mechanisms of GCSF using low resolution protein characterization techniques and advanced molecular dynamics simulations. Computational and Structural Biotechnology Journal, 2022, 20, 1439-1455.	4.1	4
3	Systematic Studies on Stabilization of AAV Vector Formulations by Lyophilization. Journal of Pharmaceutical Sciences, 2022, 111, 2288-2298.	3.3	7
4	It is Never Too Late for a Cocktail - Development and Analytical Characterization of Fixed-dose Antibody Combinations. Journal of Pharmaceutical Sciences, 2022, 111, 2149-2157.	3.3	2
5	Combining Unfolding Reversibility Studies and Molecular Dynamics Simulations to Select Aggregation-Resistant Antibodies. Molecular Pharmaceutics, 2021, 18, 2242-2253.	4.6	8
6	Comparison of Different Liquid Chromatography-Based Purification Strategies for Adeno-Associated Virus Vectors. Pharmaceutics, 2021, 13, 748.	4.5	24
7	DMSO as new, counterintuitive excipient for freeze-drying human keratinocytes. European Journal of Pharmaceutical Sciences, 2021, 160, 105746.	4.0	5
8	The Role of Cyclodextrins against Interface-Induced Denaturation in Pharmaceutical Formulations: A Molecular Dynamics Approach. Molecular Pharmaceutics, 2021, 18, 2322-2333.	4.6	18
9	100% Control of Controlled Ice Nucleation Vials by Camera-Supported Optical Inspection in Freeze-Drying. PDA Journal of Pharmaceutical Science and Technology, 2021, , pdajpst.2020.012575.	0.5	0
10	Application of Tunable Resistive Pulse Sensing for the Quantification of Submicron Particles in Pharmaceutical Monoclonal Antibody Preparations. Journal of Pharmaceutical Sciences, 2021, 110, 3541-3545.	3.3	8
11	Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab. Translational Vision Science and Technology, 2021, 10, 21.	2.2	1
12	Current Approaches of Preservation of Cells During (freeze-) Drying. Journal of Pharmaceutical Sciences, 2021, 110, 2873-2893.	3.3	21
13	Evaluation of release and pharmacokinetics of hexadecylphosphocholine (miltefosine) in phosphatidyldiglycerol-based thermosensitive liposomes. Biochimica Et Biophysica Acta - Biomembranes, 2021, 1863, 183698.	2.6	2
14	Minimizing Oxidation of Freeze-Dried Monoclonal Antibodies in Polymeric Vials Using a Smart Packaging Approach. Pharmaceutics, 2021, 13, 1695.	4.5	6
15	Calorimetric Investigation of the Relaxation Phenomena in Amorphous Lyophilized Solids. Pharmaceutics, 2021, 13, 1735.	4.5	6
16	The impact of immunogenicity on therapeutic antibody pharmacokinetics: A preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance. MAbs, 2021, 13, 1995929.	5.2	6
17	Shape Characterization of Subvisible Particles Using Dynamic Imaging Analysis. Journal of Pharmaceutical Sciences, 2020, 109, 375-379.	3.3	10
18	Overcoming challenges in co-formulation of proteins with contradicting stability profiles - EPO plus G-CSF. European Journal of Pharmaceutical Sciences, 2020, 141, 105073.	4.0	5

#	Article	IF	Citations
19	Intrinsic Differential Scanning Fluorimetry for Fast and Easy Identification of Adeno-Associated Virus Serotypes. Journal of Pharmaceutical Sciences, 2020, 109, 854-862.	3.3	17
20	Exploring Chemical Space for New Substances to Stabilize a Therapeutic Monoclonal Antibody. Journal of Pharmaceutical Sciences, 2020, 109, 301-307.	3.3	6
21	Orthogonal Techniques to Study the Effect of pH, Sucrose, and Arginine Salts on Monoclonal Antibody Physical Stability and Aggregation During Long-Term Storage. Journal of Pharmaceutical Sciences, 2020, 109, 584-594.	3.3	26
22	Advancing Therapeutic Protein Discovery and Development through Comprehensive Computational and Biophysical Characterization. Molecular Pharmaceutics, 2020, 17, 426-440.	4.6	25
23	Biophysical Characterization of Binary Therapeutic Monoclonal Antibody Mixtures. Molecular Pharmaceutics, 2020, 17, 2971-2986.	4.6	4
24	Modulated Scanning Fluorimetry Can Quickly Assess Thermal Protein Unfolding Reversibility in Microvolume Samples. Molecular Pharmaceutics, 2020, 17, 2638-2647.	4.6	17
25	Study of the interaction between a novel, protein-stabilizing dipeptide and Interferon-alpha-2a by construction of a Markov state model from molecular dynamics simulations. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 149, 105-112.	4.3	5
26	Formulations That Suppress Aggregation During Long-Term Storage of a Bispecific Antibody are Characterized by High Refoldability and Colloidal Stability. Journal of Pharmaceutical Sciences, 2020, 109, 2048-2058.	3.3	10
27	Primary and Secondary Binding of Exenatide to Liposomes. Biophysical Journal, 2020, 118, 600-611.	0.5	4
28	Nonspherical Nanoparticle Shape Stability Is Affected by Complex Manufacturing Aspects: Its Implications for Drug Delivery and Targeting. Advanced Healthcare Materials, 2019, 8, e1900352.	7.6	23
29	Generation, Characterization, and Quantitative Bioanalysis of Drug/Anti-drug Antibody Immune Complexes to Facilitate Dedicated In Vivo Studies. Pharmaceutical Research, 2019, 36, 129.	3.5	15
30	Structure-based discovery of a new protein-aggregation breaking excipient. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 144, 207-216.	4.3	6
31	Test models for the evaluation of immunogenicity of protein aggregates. International Journal of Pharmaceutics, 2019, 559, 192-200.	5.2	11
32	Silicone Oil-Free Polymer Syringes for the Storage of Therapeutic Proteins. Journal of Pharmaceutical Sciences, 2019, 108, 1148-1160.	3.3	24
33	Cellular uptake of self-assembled phytantriol-based hexosomes is independent of major endocytic machineries. Journal of Colloid and Interface Science, 2019, 553, 820-833.	9.4	21
34	Do interactions between protein and phospholipids influence the release behavior from lipid-based exenatide depot systems?. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 142, 61-69.	4.3	3
35	Immunomodulatory asthma therapy in the equine animal model: A doseâ€response study and evaluation of a longâ€term effect. Immunity, Inflammation and Disease, 2019, 7, 130-149.	2.7	11
36	Application of interpretable artificial neural networks to early monoclonal antibodies development. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 141, 81-89.	4.3	48

#	Article	IF	Citations
37	Development of a convenient method for the determination of dimethyl sulfoxide in lyophilised pharmaceuticals by static headspace gas chromatography-mass spectrometry. Analytical Methods, 2019, 11, 2119-2122.	2.7	7
38	Rapid sample-saving biophysical characterisation and long-term storage stability of liquid interferon alpha2a formulations: Is there a correlation?. International Journal of Pharmaceutics, 2019, 562, 42-50.	5.2	15
39	Evaluation of a 3D Human Artificial Lymph Node as Test Model for the Assessment of Immunogenicity of Protein Aggregates. Journal of Pharmaceutical Sciences, 2019, 108, 2358-2366.	3.3	18
40	The ReFOLD assay for protein formulation studies and prediction of protein aggregation during long-term storage. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 137, 131-139.	4.3	22
41	Microwave-Assisted Freeze-Drying of Monoclonal Antibodies: Product Quality Aspects and Storage Stability. Pharmaceutics, 2019, 11, 674.	4.5	18
42	Vesicular phospholipid gels as drug delivery systems for small molecular weight drugs, peptides and proteins: State of the art review. International Journal of Pharmaceutics, 2019, 557, 1-8.	5.2	23
43	Comparison of ice fog methods and monitoring of controlled nucleation success after freeze-drying. International Journal of Pharmaceutics, 2019, 558, 18-28.	5.2	18
44	New studies on leachables in commercial scale protein drug filling lines using stir bar sorptive extraction coupled with TD-GCâ€“MS and UPLC/QTOF-MS/MS analytics. International Journal of Pharmaceutics, 2019, 555, 404-419.	5.2	20
45	Application of water-soluble polyvinyl alcohol-based film patches on laser microporated skin facilitates intradermal macromolecule and nanoparticle delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 128, 119-130.	4.3	28
46	Isothermal chemical denaturation as a complementary tool to overcome limitations of thermal differential scanning fluorimetry in predicting physical stability of protein formulations. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 125, 106-113.	4.3	38
47	A pilot study using a novel pyrotechnically driven prototype applicator for epidermal powder immunization in piglets. International Journal of Pharmaceutics, 2018, 545, 215-228.	5.2	5
48	Engineered hybrid spider silk particles as delivery system for peptide vaccines. Biomaterials, 2018, 172, 105-115.	11.4	44
49	Evaluation of stir-bar sorptive extraction coupled with thermal desorption GCâ€“MS for the detection of leachables from polymer single use systems to drugs. Journal of Pharmaceutical and Biomedical Analysis, 2018, 152, 66-73.	2.8	6
50	The stress regulator FKBP51: a novel and promising druggable target for the treatment of persistent pain states across sexes. Pain, 2018, 159, 1224-1234.	4.2	46
51	CONTAMINATION OF ANTI-VEGF DRUGS FOR INTRAVITREAL INJECTION. Retina, 2018, 38, 2088-2095.	1.7	23
52	A comparison of nanoparticulate CpG immunotherapy with and without allergens in spontaneously equine asthmaâ€affected horses, an animal model. Immunity, Inflammation and Disease, 2018, 6, 81-96.	2.7	16
53	Pharmacological Modulation of the Psychiatric Risk Factor FKBP51 Alters Efficiency of Common Antidepressant Drugs. Frontiers in Behavioral Neuroscience, 2018, 12, 262.	2.0	29
54	A Comparison of Controlled Ice Nucleation Techniques for Freeze-Drying of a Therapeutic Antibody. Journal of Pharmaceutical Sciences, 2018, 107, 2748-2754.	3.3	16

#	Article	IF	Citations
55	A New Approach to Study the Physical Stability of Monoclonal Antibody Formulationsâ€"Dilution From a Denaturant. Journal of Pharmaceutical Sciences, 2018, 107, 3007-3013.	3.3	19
56	Expanding Bedside Filtrationâ€"A Powerful Tool to Protect Patients From Protein Aggregates. Journal of Pharmaceutical Sciences, 2018, 107, 2775-2788.	3.3	12
57	Does controlled nucleation impact the properties and stability of lyophilized monoclonal antibody formulations?. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 129, 134-144.	4.3	12
58	Progress in formulation development and sterilisation of freeze-dried oligodeoxynucleotide-loaded gelatine nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 129, 10-20.	4.3	10
59	New insights into process understanding of solid lipid extrusion (SLE) of extruded lipid implants for sustained protein delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 130, 11-21.	4.3	7
60	Binding of HSA to Macromolecular pHPMA Based Nanoparticles for Drug Delivery: An Investigation Using Fluorescence Methods. Langmuir, 2018, 34, 7998-8006.	3.5	12
61	Immune responses induced by nano-self-assembled lipid adjuvants based on a monomycoloyl glycerol analogue after vaccination with the Chlamydia trachomatis major outer membrane protein. Journal of Controlled Release, 2018, 285, 12-22.	9.9	17
62	Zn2+-triggered self-assembly of Gonadorelin [6-D-Phe] to produce nanostructures and fibrils. Scientific Reports, 2018, 8, 11280.	3.3	6
63	Significant Drying Time Reduction Using Microwave-Assisted Freeze-Drying for a Monoclonal Antibody. Journal of Pharmaceutical Sciences, 2018, 107, 2538-2543.	3.3	25
64	Evaluation of Heat Flux Measurement as a New Process Analytical Technology Monitoring Tool in Freeze Drying. Journal of Pharmaceutical Sciences, 2017, 106, 1249-1257.	3.3	16
65	cmRNA/lipoplex encapsulation in PLGA microspheres enables transfection via calcium phosphate cement (CPC)/PLGA composites. Journal of Controlled Release, 2017, 249, 143-149.	9.9	23
66	Twin-screw extruded lipid implants containing TRP2 peptide for tumour therapy. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 114, 79-87.	4.3	12
67	Long-term release and stability of pharmaceutical proteins delivered from solid lipid implants. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 117, 244-255.	4.3	23
68	Thermo-Optical Protein Characterization for Straightforward Preformulation Development. Journal of Pharmaceutical Sciences, 2017, 106, 2955-2958.	3.3	11
69	Trends on Analytical Characterization of Polysorbates and Their Degradation Products in Biopharmaceutical Formulations. Journal of Pharmaceutical Sciences, 2017, 106, 1722-1735.	3.3	108
70	Lyophilized Drug Product Cake Appearance: What Is Acceptable?. Journal of Pharmaceutical Sciences, 2017, 106, 1706-1721.	3.3	145
71	Needle-Free Injection of Vesicular Phospholipid Gelsâ€"A Novel Approach to Overcome an Administration Hurdle for Semisolid Depot Systems. Journal of Pharmaceutical Sciences, 2017, 106, 968-972.	3.3	10
72	Stress-responsive FKBP51 regulates AKT2-AS160 signaling and metabolic function. Nature Communications, 2017, 8, 1725.	12.8	82

#	Article	IF	Citations
73	Impact of plasma protein binding on cargo release by thermosensitive liposomes probed by fluorescence correlation spectroscopy. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 119, 215-223.	4.3	23
74	Scale-up of water-based spider silk film casting using a film applicator. International Journal of Pharmaceutics, 2017, 532, 13-20.	5.2	4
75	Characterization of Lipid-Based Hexosomes as Versatile Vaccine Carriers. Molecular Pharmaceutics, 2016, 13, 3945-3954.	4.6	31
76	Optimisation of one-step desolvation and scale-up of gelatine nanoparticle production. Journal of Microencapsulation, 2016, 33, 595-604.	2.8	26
77	Asymmetrical Flow Field Flow Fractionation: A Useful Tool for the Separation of Protein Pharmaceuticals and Particulate Systems. Advances in Delivery Science and Technology, 2016, , 467-488.	0.4	3
78	Origin of Aggregate Formation in Antibody Crystal Suspensions Containing PEG. Journal of Pharmaceutical Sciences, 2016, 105, 1059-1065.	3.3	5
79	Utilisation of antibody microarrays for the selection of specific and informative antibodies from recombinant library binders of unknown quality. New Biotechnology, 2016, 33, 574-581.	4.4	10
80	Two Decades of Publishing Excellence in Pharmaceutical Biotechnology. Journal of Pharmaceutical Sciences, 2015, 104, 290-300.	3.3	15
81	Growth factor release by vesicular phospholipid gels: in-vitro results and application for rotator cuff repair in a rat model. BMC Musculoskeletal Disorders, 2015, 16, 82.	1.9	19
82	Recent insights into cutaneous immunization: How to vaccinate via the skin. Vaccine, 2015, 33, 4663-4674.	3.8	78
83	Particle contamination of parenteralia and in-line filtration of proteinaceous drugs. International Journal of Pharmaceutics, 2015, 496, 250-267.	5.2	23
84	The â€œNew Polyethylene Glycol Dilemmaâ€• Polyethylene Glycol Impurities and Their Paradox Role in mAb Crystallization. Journal of Pharmaceutical Sciences, 2015, 104, 1938-1945.	3.3	14
85	Non-spherical micro- and nanoparticles: fabrication, characterization and drug delivery applications. Expert Opinion on Drug Delivery, 2015, 12, 481-492.	5.0	58
86	Head to Head Comparison of the Formulation and Stability of Concentrated Solutions of HESylated versus PEGylated Anakinra. Journal of Pharmaceutical Sciences, 2015, 104, 515-526.	3.3	26
87	The effect of steam sterilization on recombinant spider silk particles. International Journal of Pharmaceutics, 2015, 481, 125-131.	5.2	13
88	Stability of collapse lyophilized influenza vaccine formulations. International Journal of Pharmaceutics, 2015, 483, 131-141.	5.2	15
89	Investigation of the Immunogenicity of Different Types of Aggregates of a Murine Monoclonal Antibody in Mice. Pharmaceutical Research, 2015, 32, 430-444.	3.5	66
90	Quantitative detection of drug dose and spatial distribution in the lung revealed by Cryoslicing Imaging. Journal of Pharmaceutical and Biomedical Analysis, 2015, 102, 129-136.	2.8	14

#	Article	IF	Citations
91	Impact of implant composition of twin-screw extruded lipid implants on the release behavior. International Journal of Pharmaceutics, 2015, 493, 102-110.	5.2	12
92	Water-based preparation of spider silk films as drug delivery matrices. Journal of Controlled Release, 2015, 213, 134-141.	9.9	25
93	Influence of particle size, an elongated particle geometry, and adjuvants on dendritic cell activation. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 94, 542-549.	4.3	21
94	CMC determination of nonionic surfactants in protein formulations using ultrasonic resonance technology. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 92, 8-14.	4.3	18
95	Dose Levels in Particulate-Containing Formulations Impact Anti-drug Antibody Responses to Murine Monoclonal Antibody in Mice. Journal of Pharmaceutical Sciences, 2015, 104, 1610-1621.	3.3	29
96	Freeze-drying of HESylated IFNÎ±-2b: Effect of HESylation on storage stability in comparison to PEGylation. International Journal of Pharmaceutics, 2015, 495, 608-611.	5.2	6
97	Protein stability in pulmonary drug delivery via nebulization. Advanced Drug Delivery Reviews, 2015, 93, 79-94.	13.7	81
98	Calcium Alginate Gels as Stem Cell Matrix â€“ Making Paracrine Stem Cell Activity Available for Enhanced Healing after Surgery. PLoS ONE, 2015, 10, e0118937.	2.5	51
99	Thermosensitive liposomal drug delivery systems: state of the art review. International Journal of Nanomedicine, 2014, 9, 4387.	6.7	203
100	Toward intradermal vaccination: preparation of powder formulations by collapse freeze-drying. Pharmaceutical Development and Technology, 2014, 19, 213-222.	2.4	11
101	Labelâ€Free Flow Cytometry Analysis of Subvisible Aggregates in Liquid IgG1 Antibody Formulations. Journal of Pharmaceutical Sciences, 2014, 103, 90-99.	3.3	28
102	In vivo investigation of twin-screw extruded lipid implants for vaccine delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 87, 338-346.	4.3	13
103	Thatâ€™s cool! â€“ Nebulization of thermolabile proteins with a cooled vibrating mesh nebulizer. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 87, 357-365.	4.3	24
104	Influence of particle geometry and PEGylation on phagocytosis of particulate carriers. International Journal of Pharmaceutics, 2014, 465, 159-164.	5.2	74
105	Stability and activity of hydroxyethyl starch-coated polyplexes in frozen solutions or lyophilizates. International Journal of Pharmaceutics, 2014, 469, 50-58.	5.2	10
106	Antibody Responses in Mice to Particles Formed from Adsorption of a Murine Monoclonal Antibody onto Glass Microparticles. Journal of Pharmaceutical Sciences, 2014, 103, 78-89.	3.3	23
107	High Throughput Prediction of the Long-Term Stability of Pharmaceutical Macromolecules from Short-Term Multi-Instrument Spectroscopic Data. Journal of Pharmaceutical Sciences, 2014, 103, 828-839.	3.3	21
108	Novel microscale approaches for easy, rapid determination of protein stability in academic and commercial settings. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 2241-2250.	2.3	76

#	Article	IF	Citations
109	Encapsulation of antigen-loaded silica nanoparticles into microparticles for intradermal powder injection. European Journal of Pharmaceutical Sciences, 2014, 63, 154-166.	4.0	11
110	Protein HESylation for half-life extension: Synthesis, characterization and pharmacokinetics of HESylated anakinra. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 87, 378-385.	4.3	62
111	Prediction of protein degradation during vibrating mesh nebulization via a high throughput screening method. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 87, 386-394.	4.3	20
112	Characterization and compatibility of hydroxyethyl starchâ€“polyethylenimine copolymers for DNA delivery. Journal of Biomaterials Science, Polymer Edition, 2014, 25, 855-871.	3.5	11
113	Challenges for PEGylated Proteins and Alternative Half-Life Extension Technologies Based on Biodegradable Polymers. ACS Symposium Series, 2013, , 215-233.	0.5	14
114	Application of different analytical methods for the characterization of non-spherical micro- and nanoparticles. International Journal of Pharmaceutics, 2013, 453, 620-629.	5.2	37
115	Can Controlled Ice Nucleation Improve Freezeâ€Drying of Highlyâ€Concentrated Protein Formulations?. Journal of Pharmaceutical Sciences, 2013, 102, 3915-3919.	3.3	39
116	Flow Imaging Microscopy for Protein Particle Analysisâ€”A Comparative Evaluation of Four Different Analytical Instruments. AAPS Journal, 2013, 15, 1200-1211.	4.4	90
117	In vitro effects of <scp>C</scp>p<scp>G</scp> oligodeoxynucleotides delivered by gelatin nanoparticles on canine peripheral blood mononuclear cells of atopic and healthy dogs â€“ a pilot study. Veterinary Dermatology, 2013, 24, 494.	1.2	10
118	Weak antibodyâ€“cyclodextrin interactions determined by quartz crystal microbalance and dynamic/static light scattering. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 781-789.	4.3	18
119	How Subvisible Particles Become Invisibleâ€”Relevance of the Refractive Index for Protein Particle Analysis. Journal of Pharmaceutical Sciences, 2013, 102, 1434-1446.	3.3	88
120	A critical evaluation of microcalorimetry as a predictive tool for long term stability of liquid protein formulations: Granulocyte Colony Stimulating Factor (GCSF). European Journal of Pharmaceutics and Biopharmaceutics, 2013, 84, 145-155.	4.3	15
121	The Role of Polysorbate 80 and HPÎ²CD at the Air-Water Interface of IgG Solutions. Pharmaceutical Research, 2013, 30, 117-130.	3.5	36
122	Pharmaceutical feasibility of sub-visible particle analysis in parenterals with reduced volume light obscuration methods. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 1084-1087.	4.3	13
123	The effect of molar mass and degree of hydroxyethylation on the controlled shielding and deshielding of hydroxyethyl starch-coated polyplexes. Biomaterials, 2013, 34, 2530-2538.	11.4	68
124	Studies on the lipase-induced degradation of lipid-based drug delivery systems. Part II â€“ Investigations on the mechanisms leading to collapse of the lipid structure. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 84, 456-463.	4.3	9
125	Recent advances and further challenges in lyophilization. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 162-169.	4.3	135
126	Refixation of the supraspinatus tendon in a rat modelâ€”influence of continuous growth factor application on tendon structure. Journal of Orthopaedic Research, 2013, 31, 300-305.	2.3	31

#	Article	IF	Citations
127	Influence of Hydroxypropylâ€Betaâ€Cyclodextrin on the Stability of Dilute and Highly Concentrated Immunoglobulin G Formulations. Journal of Pharmaceutical Sciences, 2013, 102, 4121-4131.	3.3	23
128	Quality Control of Protein Crystal Suspensions Using Microflow Imaging and Flow Cytometry. Journal of Pharmaceutical Sciences, 2013, 102, 3860-3866.	3.3	5
129	Microâ€“Flow Imaging and Resonant Mass Measurement (Archimedes) â€“ Complementary Methods to Quantitatively Differentiate Protein Particles and Silicone Oil Droplets. Journal of Pharmaceutical Sciences, 2013, 102, 2152-2165.	3.3	115
130	Comparison of the Effects of Early Pregnancy with Human Interferon, Alpha 2 (IFNA2), on Gene Expression in Bovine Endometrium1. Biology of Reproduction, 2012, 86, 46.	2.7	86
131	Towards an inhalativein vivoapplication of immunomodulating gelatin nanoparticles in horse-related preformulation studies. Journal of Microencapsulation, 2012, 29, 615-625.	2.8	24
132	Preparation and validation of a skin model for the evaluation of intradermal powder injection devices. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 360-368.	4.3	7
133	A New Approach to Achieve Controlled Ice Nucleation of Supercooled Solutions During the Freezing Step in Freezeâ€Drying. Journal of Pharmaceutical Sciences, 2012, 101, 4409-4413.	3.3	31
134	Release pathways of interferon Î±2a molecules from lipid twin screw extrudates revealed by single molecule fluorescence microscopy. Journal of Controlled Release, 2012, 162, 295-302.	9.9	11
135	Mechanistic studies on the release of lysozyme from twin-screw extruded lipid implants. Journal of Controlled Release, 2012, 163, 187-194.	9.9	20
136	In-vivo biodegradation of extruded lipid implants in rabbits. Journal of Controlled Release, 2012, 163, 195-202.	9.9	13
137	Systematic Investigation of the Effect of Lyophilizate Collapse on Pharmaceutically Relevant Proteins, Part 2: Stability During Storage at Elevated Temperatures. Journal of Pharmaceutical Sciences, 2012, 101, 2288-2306.	3.3	63
138	A Nebulized Gelatin Nanoparticle-Based CpG Formulation is Effective in Immunotherapy of Allergic Horses. Pharmaceutical Research, 2012, 29, 1650-1657.	3.5	42
139	Recombinant spider silk particles for controlled delivery of protein drugs. Biomaterials, 2012, 33, 1554-1562.	11.4	94
140	Controlled shielding and deshielding of gene delivery polyplexes using hydroxyethyl starch (HES) and alpha-amylase. Journal of Controlled Release, 2012, 159, 92-103.	9.9	78
141	Particles in Therapeutic Protein Formulations, Part 1: Overview of Analytical Methods. Journal of Pharmaceutical Sciences, 2012, 101, 914-935.	3.3	191
142	Protein Instability and Immunogenicity: Roadblocks to Clinical Application of Injectable Protein Delivery Systems for Sustained Release. Journal of Pharmaceutical Sciences, 2012, 101, 946-954.	3.3	205
143	Immunostimulation of bronchoalveolar lavage cells from recurrent airway obstruction-affected horses by different CpG-classes bound to gelatin nanoparticles. Veterinary Immunology and Immunopathology, 2011, 144, 79-87.	1.2	23
144	Protein stabilization by cyclodextrins in the liquid and dried state. Advanced Drug Delivery Reviews, 2011, 63, 1086-1106.	13.7	150

#	Article	IF	Citations
145	Recombinant spider silk particles as drug delivery vehicles. Biomaterials, 2011, 32, 2233-2240.	11.4	137
146	Delivery of Immunostimulatory RNA Oligonucleotides by Gelatin Nanoparticles Triggers an Efficient Antitumoral Response. Journal of Immunotherapy, 2010, 33, 935-944.	2.4	26
147	New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: Part I â€" Formulation development and in-vitro characterization. Journal of Controlled Release, 2010, 143, 143-150.	9.9	86
148	Size of thermosensitive liposomes influences content release. Journal of Controlled Release, 2010, 147, 436-443.	9.9	106
149	New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: In-vivo characterization. Journal of Controlled Release, 2010, 148, 368-372.	9.9	133
150	Inhibition of Agitationâ€Induced Aggregation of an IgGâ€Antibody by Hydroxypropylâ€Î²â€Cyclodextrin. Journal of Pharmaceutical Sciences, 2010, 99, 1193-1206.	3.3	95
151	Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: Essential need to use orthogonal methods to assure the quality of therapeutic protein products. Journal of Pharmaceutical Sciences, 2010, 99, 2200-2208.	3.3	185
152	Ultrasonic resonator technology as a new quality control method evaluating gelatin nanoparticles. Journal of Microencapsulation, 2010, 27, 242-252.	2.8	8
153	Matrix-loaded biodegradable gelatin nanoparticles as new approach to improve drug loading and delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 1-9.	4.3	124
154	Lipid extrudates as novel sustained release systems for pharmaceutical proteins. Journal of Controlled Release, 2009, 134, 177-185.	9.9	55
155	Studies on the lipase induced degradation of lipid based drug delivery systems. Journal of Controlled Release, 2009, 140, 27-33.	9.9	26
156	Overlooking Subvisible Particles in Therapeutic Protein Products: Gaps That May Compromise Product Quality. Journal of Pharmaceutical Sciences, 2009, 98, 1201-1205.	3.3	492
157	Microbubbles as ultrasound triggered drug carriers. Journal of Pharmaceutical Sciences, 2009, 98, 1935-1961.	3.3	133
158	Characterization of ultrasound-mediated destruction of drug-loaded microbubbles using an improved in vitro model. Applied Acoustics, 2009, 70, 1323-1329.	3.3	5
159	Delivery by Cationic Gelatin Nanoparticles Strongly Increases the Immunostimulatory Effects of CpG Oligonucleotides. Pharmaceutical Research, 2008, 25, 551-562.	3.5	117
160	Processing Conditions for the Formation of Spider Silk Microspheres. ChemSusChem, 2008, 1, 413-416.	6.8	103
161	Formulation development of freeze-dried oligonucleotide-loaded gelatin nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 514-521.	4.3	48
162	Targeting CpG Oligonucleotides to the Lymph Node by Nanoparticles Elicits Efficient Antitumoral Immunity. Journal of Immunology, 2008, 181, 2990-2998.	0.8	150

#	Article	IF	Citations
163	Method for Quantifying the PEGylation of Gelatin Nanoparticle Drug Carrier Systems Using Asymmetrical Flow Field-Flow Fractionation and Refractive Index Detection. Analytical Chemistry, 2007, 79, 4574-4580.	6.5	40
164	Application and Drying of Protein Drug Microdroplets on Solid Surfaces. Pharmaceutical Development and Technology, 2007, 12, 61-70.	2.4	6
165	Quantitation of Aggregate Levels in a Recombinant Humanized Monoclonal Antibody Formulation by Size-Exclusion Chromatography, Asymmetrical Flow Field Flow Fractionation, and Sedimentation Velocity. Journal of Pharmaceutical Sciences, 2007, 96, 268-279.	3.3	157
166	Ultrasound Targeted Microbubble Destruction Increases Capillary Permeability in Hepatomas. Ultrasound in Medicine and Biology, 2007, 33, 1592-1598.	1.5	98
167	Mechanisms controlling protein release from lipidic implants: Effects of PEG addition. Journal of Controlled Release, 2007, 118, 161-168.	9.9	63
168	New Insight into the Role of Polyethylene Glycol Acting as Protein Release Modifier in Lipidic Implants. Pharmaceutical Research, 2007, 24, 1527-1537.	3.5	35
169	Continuous Release of rh-Interferon Î±-2a from Triglyceride Implants: Storage Stability of the Dosage Forms. Pharmaceutical Development and Technology, 2006, 11, 103-110.	2.4	18
170	NIR spectroscopyâ€"a non-destructive analytical tool for protein quantification within lipid implants. Journal of Controlled Release, 2006, 114, 261-267.	9.9	15
171	Continuous release of rh-interferon Î±-2a from triglyceride matrices. Journal of Controlled Release, 2004, 97, 67-78.	9.9	59
172	Asymmetrical Flow Field-Flow Fractionation and Multiangle Light Scattering for Analysis of Gelatin Nanoparticle Drug Carrier Systems. Analytical Chemistry, 2004, 76, 1909-1920.	6.5	105
173	The use of asymmetrical flow field-flow fractionation in pharmaceutics and biopharmaceutics. European Journal of Pharmaceutics and Biopharmaceutics, 2004, 58, 369-383.	4.3	182
174	Continuous measurement of drying rate of crystalline and amorphous systems during freezeâ€drying using an in situ microbalance technique. Journal of Pharmaceutical Sciences, 2001, 90, 1345-1355.	3.3	35
175	Formulation of Proteins in Vacuum-Dried Glasses. II. Process and Storage Stability in Sugar-Free Amino Acid Systems. Pharmaceutical Development and Technology, 1999, 4, 199-208.	2.4	101
176	Erythropoietin loaded microspheres prepared from biodegradable LPLGâ€"PEOâ€"LPLG triblock copolymers: protein stabilization and in-vitro release properties. Journal of Controlled Release, 1998, 56, 105-115.	9.9	108
177	Recombinant human erythropoietin (rhEPO) loaded poly(lactide-co-glycolide) microspheres: influence of the encapsulation technique and polymer purity on microsphere characteristics. European Journal of Pharmaceutics and Biopharmaceutics, 1998, 45, 295-305.	4.3	103
178	Microencapsulation of rh-erythropoietin, using biodegradable poly(d,l-lactide-co-glycolide): protein stability and the effects of stabilizing excipients. European Journal of Pharmaceutics and Biopharmaceutics, 1997, 43, 29-36.	4.3	183
179	Formulation of proteins in vacuum-dried glasses. I: Improved vacuum-drying of sugars using crystallising amino acids. European Journal of Pharmaceutics and Biopharmaceutics, 1997, 44, 177-185.	4.3	32